Caseous Lymphadenitis (CL)

Caseous Lymphadenitis vaccines provide protection against infection with Corynebacterium pseudotuberculosis, the causative agent of a chronic, debilitating disease affecting sheep and goats worldwide. Known colloquially as "cheesy gland disease" for the characteristic thick, caseous pus found in affected lymph nodes, CL causes significant economic losses through reduced productivity, carcass condemnation, and premature culling of affected animals. The disease is highly contagious within flocks and herds, spreading through contamination of wounds during shearing, environmental persistence of the organism, and direct contact with draining abscesses.

The pathogenesis of Caseous Lymphadenitis involves bacterial entry through skin wounds or mucosal surfaces, followed by lymphatic spread to regional lymph nodes where characteristic abscesses develop. Corynebacterium pseudotuberculosis produces phospholipase D (PLD) toxin, which damages cell membranes and allows the organism to survive within macrophages, evading immune clearance. Vaccines containing PLD toxoid stimulate antibody responses that neutralize this critical virulence factor, while whole-cell bacterin components provide additional protective immunity. This combination approach addresses both toxin-mediated pathology and bacterial persistence.

Available vaccine products include killed bacterin-toxoid formulations administered as subcutaneous injections, with several commercial products approved for use in sheep and goats. Most formulations require a two-dose primary series followed by annual boosters to maintain protective immunity. Some products combine CL antigens with clostridial components in multivalent vaccines, simplifying vaccination programs for small ruminant operations. The choice between standalone CL vaccines and combination products depends on overall flock health program requirements and prevalence of various diseases in the operation.

Regulatory approval status varies by country and product, with vaccines available through veterinary supply distributors in regions where CL represents a significant health challenge. In the United States, USDA-licensed products are available over-the-counter, while other countries may have different regulatory requirements. The economic justification for CL vaccination depends on disease prevalence, production system, and market requirements, with show animal producers and breeding operations often finding vaccination particularly valuable for maintaining herd health status and marketability.

The primary indication for Caseous Lymphadenitis vaccination is prevention of external and internal abscess formation caused by Corynebacterium pseudotuberculosis in sheep and goats. External abscesses developing in superficial lymph nodes create visible swellings that rupture and contaminate the environment with infectious material, while internal abscesses affecting lungs, liver, kidneys, and deep lymph nodes cause chronic wasting and reduced productivity. Vaccination significantly reduces the incidence and severity of abscess development in exposed animals, though it may not completely prevent infection in heavily challenged environments.

Breeding stock protection represents a high-priority indication for CL vaccination, as the disease causes reproductive losses and chronic ill-thrift that reduce breeding efficiency. Infected ewes and does transmit bacteria to offspring through contaminated colostrum and milk, establishing infection early in life. Vaccinating breeding females before parturition provides maternal antibody transfer to offspring and reduces environmental contamination during the high-risk periparturient period. Rams and bucks should also be vaccinated, as shearing wounds and breeding injuries provide entry points for infection.

Show animal and sale animal preparation frequently includes CL vaccination as part of health protocols ensuring animals are free from visible abscesses and protected from exposure at high-contact events. Many show circuits and sales require health certificates that may include CL vaccination documentation or physical examination confirming absence of palpable abscesses. The reputational damage and potential legal liability associated with selling CL-infected animals makes vaccination an important risk management tool for seedstock producers.

New herd or flock additions should be vaccinated during quarantine periods before introduction to resident populations, particularly when entering operations with no history of CL. This biosecurity measure reduces the risk of introducing disease through purchased animals while allowing development of protective immunity before exposure to resident animal contact. Testing combined with vaccination provides optimal protection, as animals actively shedding bacteria at purchase may not be protected by vaccination alone.

Endemic flock control programs utilize vaccination as one component of comprehensive CL management alongside culling of clinically affected animals, improved hygiene, and environmental management. In heavily infected flocks, vaccination cannot eliminate existing infections but can reduce new case rates and environmental contamination over time. Multi-year vaccination programs combined with aggressive culling of animals developing abscesses gradually reduce prevalence, though complete elimination typically requires depopulation and restocking with CL-free animals.

Standard dosage for Caseous Lymphadenitis vaccines is 2 mL administered subcutaneously, with most products recommending a two-dose primary series for animals not previously vaccinated. The initial dose primes the immune system, followed by a second dose administered 3-4 weeks later that boosts antibody levels to protective concentrations. Animals receiving only single doses may not achieve adequate protection and should complete the primary series before being considered immunized. The importance of the booster dose cannot be overstated, as single-dose vaccination is a common cause of apparent vaccine failure.

Annual revaccination is recommended to maintain protective immunity, with timing ideally 2-4 weeks before anticipated periods of increased risk. For breeding flocks, vaccination 2-4 weeks before lambing or kidding optimizes maternal antibody transfer while providing peak immunity during the high-risk parturient period. For meat animals, vaccination should be completed well before marketing age to allow injection site reactions to resolve. Pre-shearing vaccination provides protection during the high-risk wound exposure period, though injection site swelling should not be confused with early abscess development.

Administration technique requires proper attention to subcutaneous injection protocols. The preferred injection site is the neck region, posterior to the ear and anterior to the shoulder, where subcutaneous tissue is accessible and injection site reactions can be easily monitored. The wool or hair should be parted, skin cleaned if visibly soiled, and the needle inserted at an angle that deposits vaccine beneath the skin rather than into muscle tissue. Aspiration before injection confirms proper needle placement outside blood vessels.

Needle selection for subcutaneous injection typically involves 18-20 gauge needles of appropriate length for the animal's size and body condition. Small breeds and young animals may require shorter, finer needles, while heavily wooled sheep benefit from longer needles that penetrate through the fleece. Needle changes between animals reduce disease transmission risk and maintain sharpness for accurate injection. Multi-dose vaccine bottles should be handled aseptically, with a new sterile needle used for each withdrawal to prevent contamination.

Combination vaccines containing CL components along with clostridial antigens follow manufacturer-specific dosing instructions, which may differ from standalone CL products. Some combinations require larger injection volumes or different injection site recommendations. When multiple vaccines are administered at the same visit, separate injection sites should be used to allow independent monitoring of reactions and avoid potential antigen interactions at a single site.

Withdrawal times for CL vaccines are typically 21 days before slaughter for meat products, though specific products should be verified on current labeling. This relatively brief withdrawal reflects the lack of antibiotic or chemical residue concerns with killed vaccine products, with the waiting period primarily allowing injection site reactions to resolve before carcass inspection. There are no milk withholding requirements for most products, making vaccination compatible with dairy goat production systems.

Caseous Lymphadenitis vaccines commonly produce injection site reactions as a normal consequence of immune stimulation, particularly with oil-adjuvanted formulations designed to enhance and prolong immune responses. Localized swelling at the injection site develops within 24-48 hours, ranging from small nodules of 1-2 cm to more substantial reactions in some individuals. These reactions represent the inflammatory response necessary for effective immunity and typically resolve over 2-4 weeks without treatment. Some residual firmness may persist longer but is not clinically significant.

The distinction between normal vaccine reactions and early CL abscesses is important for accurate diagnosis and management. Vaccine site reactions occur precisely at the injection location, develop within days of vaccination, and gradually decrease in size over weeks. True CL abscesses develop in lymph node locations (not necessarily at injection sites), typically appear weeks to months after potential exposure, and progressively enlarge before eventually rupturing. Any lumps developing in lymph node regions should be evaluated for CL regardless of vaccination status.

Systemic reactions to CL vaccination may include transient fever, reduced appetite, and lethargy for 24-48 hours following administration. These responses are more common after the second dose when the immune system mounts an anamnestic response. Lactating animals may show temporary milk production decreases that resolve within several days. Body weight gain may be slightly reduced around vaccination time, though long-term production effects are not expected when animals are otherwise healthy.

Severe adverse reactions are uncommon but can include marked injection site swelling, abscessation at the vaccine site, or hypersensitivity responses. Vaccine site abscesses are usually sterile inflammatory reactions rather than true bacterial infections, but secondary contamination can occur if skin integrity is compromised. Animals showing persistent or enlarging injection site reactions beyond 4-6 weeks should be examined by a veterinarian. Anaphylactic reactions characterized by acute respiratory distress, collapse, or death are rare but require immediate veterinary attention if observed.

Chronic granulomatous reactions at injection sites have been reported with some adjuvant systems, creating persistent nodules that may be palpable for extended periods. These reactions are cosmetically undesirable in show animals and may cause confusion with early abscess formation. The incidence of significant local reactions can be minimized by proper subcutaneous injection technique, appropriate needle selection, and attention to vaccine handling and storage recommendations.

Caseous Lymphadenitis vaccination is contraindicated in animals showing clinical signs of active illness, significant debilitation, or fever. The immune response to vaccination requires metabolic resources and immunological competence; vaccination of sick animals results in suboptimal protection and may exacerbate existing health problems. Animals should be evaluated for overall health status before vaccination, with vaccination postponed until clinical conditions resolve. Concurrent parasitism, malnutrition, or chronic disease should be addressed as part of comprehensive health management.

Animals with known hypersensitivity to vaccine components should not receive additional doses of the same product. While true anaphylaxis is rare, animals that have experienced severe reactions to previous CL vaccinations should be identified and alternative management approaches considered. These may include enhanced biosecurity measures, isolation from infected flocks, or trial with alternative vaccine formulations under veterinary supervision with appropriate emergency preparedness.

Vaccination within 21 days of slaughter is contraindicated due to meat withdrawal requirements and the potential for injection site reactions to cause carcass trimming or condemnation at processing. Animals destined for imminent sale or slaughter should not be vaccinated unless the intended purpose allows adequate time for withdrawal completion and reaction resolution. Marketing timelines should be considered when planning vaccination schedules for meat animals.

Vaccination of animals with existing CL abscesses will not resolve current infections and may create false security regarding disease status. The vaccines are preventive rather than therapeutic and do not eliminate established Corynebacterium pseudotuberculosis infections. Animals with palpable abscesses should be isolated and managed according to flock CL control protocols, which may include culling rather than vaccination. Vaccination may still be indicated to prevent additional abscess development, but expectations should be appropriate.

Caseous Lymphadenitis vaccines can generally be administered concurrently with other killed bacterial and viral vaccines without significant immunological interference. The most common co-administration involves combination with clostridial vaccines, either as pre-mixed combination products or as separate injections given at the same handling event. When multiple vaccines are given simultaneously, separate injection sites in different anatomical locations allow independent assessment of any reactions and avoid potential local interactions between adjuvant systems.

Live attenuated vaccines present theoretical interaction concerns when administered concurrently with killed products, as the immune response to one antigen may influence responses to others. General recommendations suggest spacing live and killed vaccine administrations by 1-2 weeks when possible, though practical management constraints often require concurrent administration. No specific adverse interactions between CL vaccines and commonly used live vaccines have been documented in small ruminants, but veterinary guidance is appropriate when designing complex vaccination protocols.

Immunosuppressive conditions and treatments reduce CL vaccine effectiveness. Corticosteroids, whether administered therapeutically or produced endogenously during stress, impair immune response development. Vaccination should be timed to avoid periods of predictable stress such as transport, weather extremes, or diet changes. Animals receiving immunosuppressive therapy should have vaccination postponed until treatment is complete and immune function recovers. Chronic conditions affecting immune competence may result in incomplete protection despite appropriate vaccination.

Antimicrobial therapy does not directly interfere with CL vaccine responses since the vaccine contains killed organisms incapable of replication. However, animals receiving antibiotics are typically being treated for active infections, making them poor vaccination candidates on that basis. Completing antibiotic therapy and allowing recovery from the underlying condition before vaccination optimizes both the immune response to vaccine and overall animal welfare. Standard deworming treatments do not interact with CL vaccination and can be administered according to normal protocols.

Handler safety during CL vaccine administration requires standard precautions for injectable biological products. Accidental self-injection should be avoided through proper needle handling techniques and use of appropriate restraint equipment. While Corynebacterium pseudotuberculosis can cause human infection through wound contamination, the killed organisms in vaccines pose minimal zoonotic risk. Nevertheless, any accidental needlestick should be cleaned thoroughly and medical advice sought, particularly for immunocompromised individuals. The adjuvant systems in some vaccines can cause significant local tissue reactions if inadvertently injected into humans.

Vaccinated animals may still become infected with CL when exposed to heavy environmental contamination or direct contact with infected flockmates. Vaccination reduces infection risk and disease severity but does not provide absolute protection. Comprehensive CL control programs must include vaccination alongside biosecurity measures, environmental hygiene, identification and management of infected animals, and testing protocols. Relying solely on vaccination without addressing other transmission routes limits program effectiveness.

Serological testing for CL may be confounded by vaccine-induced antibodies, as current commercial tests cannot distinguish between vaccinated and infected animals. Testing programs in vaccinated flocks must account for this limitation, potentially requiring serial testing, culture confirmation of suspect cases, or use of pre-vaccination blood samples as baselines. Flocks participating in CL-free certification programs should coordinate vaccination and testing protocols to ensure interpretable results.

Environmental persistence of Corynebacterium pseudotuberculosis necessitates attention to premises hygiene in endemic operations. The organism survives for months in soil, organic material, and contaminated equipment. Vaccination protects individual animals but does not eliminate environmental contamination. Shearing equipment, handling facilities, and feed bunks should be cleaned and disinfected regularly. Manure management and drainage patterns should minimize persistence of infectious material in areas where animals congregate.

Antimicrobial resistance is not a direct concern with killed CL vaccines, but comprehensive herd health programs should consider judicious antimicrobial use alongside vaccination. Antibiotic treatment of CL abscesses is generally ineffective due to the organism's intracellular location and poor drug penetration into caseous material. Lancing and flushing abscesses combined with vaccination of uninfected flockmates provides better control than antimicrobial therapy while preserving antibiotic effectiveness for conditions where they are indicated.

Caseous Lymphadenitis vaccines require refrigerated storage at 2-8°C (35-46°F) throughout their shelf life and must be protected from both freezing and elevated temperatures. Freezing causes irreversible damage to adjuvant systems, resulting in altered physical appearance, reduced immunogenicity, and potentially increased injection site reactions. Vaccines that have been accidentally frozen should be discarded rather than used, as efficacy cannot be assured. Visual inspection for separation, abnormal color, or particulate matter should precede every use.

Multi-dose vials require aseptic handling to prevent bacterial contamination that could cause injection site infections. A new, sterile needle should be used for each withdrawal from the vaccine bottle, and rubber stoppers should be cleaned with alcohol before insertion. Once broached, multi-dose containers should be used within 8-10 hours under field conditions or according to manufacturer specifications. Unused vaccine remaining at the end of a vaccination session should be discarded rather than stored for future use, as sterility cannot be guaranteed.

Field transport of vaccines requires insulated containers with appropriate cooling elements to maintain temperature during the period between removal from refrigerated storage and administration. Direct sunlight and vehicle interiors can quickly elevate temperatures beyond acceptable ranges, destroying vaccine potency. Temperature monitoring during transport and field use documents appropriate handling and supports investigation of any suspected vaccine failures. Vaccines should be removed from refrigeration only in quantities that will be used promptly.

Disposal of used vaccine containers, needles, and unused product should follow local regulations for sharps and biological waste. While killed vaccines pose less environmental concern than live products, proper disposal practices maintain professional standards and regulatory compliance. Sharps containers should be used for needle disposal, and empty vaccine vials should not be repurposed for other uses. Record retention including product name, lot number, expiration date, and animals vaccinated supports traceability if product issues arise.

All breeds of sheep and goats are susceptible to Caseous Lymphadenitis infection, making vaccination broadly applicable across diverse genetic backgrounds. However, some production systems and breed types may warrant particular attention to CL prevention. Fine-wool sheep breeds including Merino and Rambouillet face significant shearing-related exposure risks, as the multiple handling events and potential for shearing wounds create repeated opportunities for bacterial entry. These operations benefit from pre-shearing vaccination programs that ensure peak immunity during high-risk periods.

Meat breeds managed in intensive or semi-intensive systems face different risk profiles than extensive pastoral operations. Higher stocking densities increase contact rates and environmental contamination levels, potentially warranting more aggressive vaccination programs. Conversely, extensively managed range flocks with minimal handling may have lower overall CL exposure and can evaluate vaccination cost-effectiveness based on historical disease incidence. Regional prevalence data and veterinary consultation help determine appropriate program intensity.

Dairy goats represent a production category with particular CL concerns due to the chronic nature of infection and its impacts on longevity and productivity. Lactating does with internal CL abscesses may show gradual weight loss and declining milk production over time, with diagnosis often made only at necropsy or during disease investigation. The relatively high individual animal value in dairy operations justifies routine vaccination and regular monitoring for abscess development. Show dairy goats face additional reputational risks from visible external abscesses.

Seedstock producers across all breeds must maintain vigilance regarding CL status due to the potential for spreading infection through animal sales. Vaccination combined with thorough physical examination of all animals before sale provides dual protection against transmission. Documentation of vaccination programs and disease-free status supports marketing claims and customer confidence. Some breed registries or show circuits may have specific CL requirements that influence vaccination program design for participating producers.

Clostridial vaccines represent the most commonly co-administered products with CL vaccines in small ruminant health programs. The foundational CD-T vaccine protecting against Clostridium perfringens types C and D and tetanus is considered essential for all sheep and goats. Many producers elect combination vaccines that include both CL and clostridial components, simplifying handling while providing comprehensive protection. Products such as Caseous D-T and various 8-way or 9-way combinations streamline vaccination protocols for operations with multiple disease concerns.

Chlamydia abortion vaccines may be indicated alongside CL vaccination in breeding flocks experiencing reproductive losses. Both conditions are endemic in many sheep-producing regions and benefit from strategic vaccination before breeding season. Coordinating multiple vaccinations requires attention to product compatibility, adequate spacing between administrations, and appropriate record keeping. Veterinary consultation helps design integrated vaccination schedules addressing flock-specific disease pressures.

Soremouth (contagious ecthyma) vaccines represent another common small ruminant vaccine that may be administered in coordination with CL vaccination. Unlike the killed CL vaccine, soremouth vaccine is a modified live product requiring attention to handling and timing considerations. The live nature of soremouth vaccine influences scheduling relative to other vaccinations, with general recommendations for spacing of 2-4 weeks between different live and killed products when possible. Operations using both vaccines should develop protocols that optimize responses to each while managing handling frequency.